If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTransense Regulatory News (TRT)

Share Price Information for Transense (TRT)

Share Price is delayed by 15 minutes
Get Live Data
48.50    0.00 (0.00%)
Bid:
48.00
Ask:
49.00
Spread: 1.00 (2.083%)
Market Cap: £7.38m
TRT Live PriceLast checked at - London Stock Exchange

Intraday Transense Share Chart

Board Changes

Today 07:00

RNS Number : 2289L
Transense Technologies PLC
07 July 2026
 

7 July 2026

Transense Technologies plc

("Transense" or the "Company")

Board Changes

Retirement of Chief Financial Officer and Appointment of Finance Director (designate)

Transense Technologies plc (AIM: TRT), the provider of specialist sensor technology and measurement solutions, announces that Melvyn Segal has informed the Board of his intention to retire from the role of Chief Financial Officer ("CFO") and Company Secretary with effect from the Company's Annual General Meeting (AGM) in November 2026. The Board also announces the appointment of Richard Michael Pearce ACA as Finance Director with effect from 1 September 2026.

Melvyn will remain with the Company in an executive capacity for a handover period until the AGM, and will subsequently remain on the Board as a non-executive director for a further year. The Board would like to thank Melvyn for his significant contribution to Transense over many years, during which the Company and its prospects have been transformed.

Richard brings over twenty years of financial, commercial and listed company experience to Transense. Since qualifying as a Chartered Accountant with Ernst & Young in 1999, he has held senior finance roles at GE Healthcare and TD Williamson, and most recently as Finance Director at Lombard Medical where he oversaw a scale-up in revenues from £6m to £25m per annum since 2018. He will initially work alongside Melvyn in a non-board role as Finance Director, with progression to the Board leading the Group's finance function when Melvyn's steps down as CFO in November 2026.

The Board welcomes Richard to his new role and we look forward to his contribution to delivery of the future growth strategy.

For further information please visit www.transense.com or contact:

Transense Technologies plc

Nigel Rogers (Executive Chairman)

Ryan Maughan (Managing Director)

Melvyn Segal (Chief Financial Officer)

Via Investor Relations

(see below)

Cavendish Capital Market Limited (Nominated Adviser and Broker)

Adrian Hadden / Callum Davidson (Corporate Finance)

Jasper Berry (Sales)

0207 220 0500

Investor Relations

Anice McNamee

Tel: +44 (0)1869 238380

Investor.relations@transense.co.uk

Notes to Editors:

Transense is headquartered in Oxfordshire, UK and its shares are traded on AIM, a market operated by the London Stock Exchange (AIM: TRT). The Company develops and supplies advanced sensor technology and measurement solutions used by some of the world's leading companies to improve performance, efficiency, and safety in demanding, mission critical applications. Transense currently operates through two active business segments:

· SAWsense - designs, supplies and licences advanced sensor solutions based on proven, patent protected Surface Acoustic Wave (SAW) technology to world leading companies in aerospace, automotive, and industrial machinery (including robotics), enabling improved efficiency and performance of their products. Key customers include GE Aerospace, Parker Meggitt, McLaren Applied, Airbus and several other confidential Tier One automotive, aerospace and industrial machinery suppliers.

 

· Translogik - develops smart, connected commercial vehicle tyre inspection equipment to many of the world's leading tyre suppliers, fleet operators and service centres. Enabling accurate measurement and digital capture of safety-critical tyre condition data, used to reduce operating costs, improve safety and provide audit records for regulatory compliance. Key customers include Bridgestone, Goodyear, Continental and Prometeon (Pirelli), and leading independent providers of vehicle fleet maintenance management software.

 In addition, Transense earns residual royalty income from Bridgestone iTrack - a tyre monitoring system for off-highway vehicles that was developed by Translogik. The associated sales, support and development infrastructure were sold to Bridgestone Corporation, the world's largest tyre producer, in June 2020, and the intellectual property was licensed exclusively to Bridgestone under a ten-year deal expiring in 2030.

Find out more at: https://www.transense.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAAKABQCBKDDOK
Date   Source Headline
12th Feb 202112:48 pmRNSFurther re. Completion of Capital Reduction
1st Feb 20217:00 amRNSNotice of Results & Investor Presentation
28th Jan 20217:00 amRNSCompletion of Capital Reduction
21st Dec 20207:00 amRNSIssue of Options
17th Dec 20201:19 pmRNSResult of AGM
17th Dec 20207:00 amRNSAGM Update, new Website & Investor Presentation
9th Dec 20207:00 amRNSEstablishment of SAW Commercial Advisory Panel
23rd Nov 20207:00 amRNSPosting of Annual Report and Notice of AGM
6th Nov 20203:38 pmRNSDirector/PDMR Shareholding
22nd Oct 20208:45 amRNSHolding(s) in Company
20th Oct 202012:09 pmRNSDirector/PDMR Shareholding
20th Oct 20207:00 amRNSFinal results for the year ended 30 June 2020
19th Oct 20207:00 amRNSChange of Nomad and Broker & AIM Rule 17 update
12th Oct 20207:00 amRNSNotice of Results and Investor Presentation
10th Sep 20207:00 amRNSFinal consideration for iTrack transfer
25th Aug 202010:23 amRNSDirector/PDMR Shareholding
24th Aug 20209:27 amRNSHolding(s) in Company (Replacement)
20th Aug 20205:02 pmRNSHolding(s) in Company
8th Jul 20204:16 pmRNSDirector/PDMR Shareholding
7th Jul 20203:38 pmRNSHolding(s) in Company
3rd Jul 202011:30 amRNSHolding(s) in Company
3rd Jul 20207:00 amRNSInvestor Presentation
1st Jul 20206:12 pmRNSHolding(s) in Company
26th Jun 20201:54 pmRNSDirector/PDMR Shareholding
26th Jun 20207:00 amRNSGrant of Options/PDMR Dealing
25th Jun 20204:41 pmRNSDirector/PDMR Shareholding
25th Jun 20202:10 pmRNSDirector/PDMR Shareholding
25th Jun 20207:01 amRNSStrategic Update
25th Jun 20207:00 amRNSBridgestone Granted Worldwide iTrack Licence
12th Jun 202010:40 amRNSUpdate relating to the JCA with Bridgestone
1st Jun 20207:00 amRNSUpdate relating to the JCA with Bridgestone
5th May 20202:39 pmRNSHolding(s) in Company
1st May 20207:00 amRNSUpdate relating to the JCA with Bridgestone
16th Mar 20207:00 amRNSFurther Working Capital Loan Agreement
20th Feb 20207:00 amRNSInterim Results
20th Feb 20207:00 amRNSInterim Results
19th Feb 20207:00 amRNSChanges to Board responsibilities
13th Feb 20207:01 amRNSNotice of Interim Results
13th Feb 20207:00 amRNSExtension to Agreement with Bridgestone
19th Dec 20194:14 pmRNSResult of AGM
19th Dec 20197:00 amRNSAGM Statement
19th Nov 20197:00 amRNSNotice of AGM
15th Nov 20194:53 pmRNSHolding(s) in Company
7th Nov 20191:13 pmRNSHolding(s) in Company
26th Sep 20197:00 amRNSFinal results for the year ended 30 June 2019
14th Aug 20199:09 amRNSHolding(s) in Company
13th Aug 20192:45 pmRNSAwards of Options
13th Aug 20197:00 amRNSJoint Collaboration Agreement with Bridgestone
30th Jul 20197:00 amRNSTrading Update
1st Jul 201912:02 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.